AGT treats first patient in clinical trial for HIV

Published: 3 June 2021

Could the autologous T cell therapy offer a cure?

The first patient has been treated in a Phase I trial of an experimental cell and gene therapy from American Gene Technologies (AGT), which the company believes could be a functional cure for HIV.

The treatment, AGT103-T, involves genetically engineering patients’ own HIV-specific CD4+ T cells to impart resistance to HIV infection. When expanded and reintroduced into the body, the cells help generate an immune response to clear HIV.  

AGT Founder and CEO Jeff Galvin said in a press release: “This project represents a major step forward in the potency of an approach that has significant theoretical and empirical momentum within the HIV cure scientific community.”

The first-in-human trial will enroll up to six patients who have HIV that is well-controlled with antiretroviral medication.